These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18977144)

  • 21. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
    Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
    Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
    Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
    Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
    Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
    Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells.
    Zheng YD; Xu XQ; Peng F; Yu JZ; Wu H
    Oncol Rep; 2011 May; 25(5):1399-405. PubMed ID: 21399878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
    Sabisz M; Wesierska-Gadek J; Skladanowski A
    Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of telomerase activity by reduction of poly(ADP-ribosyl)ation of TERT and TEP1/TP1 expression in HeLa cells with knocked down poly(ADP-ribose) polymerase-1 (PARP-1) gene.
    Ghosh U; Das N; Bhattacharyya NP
    Mutat Res; 2007 Feb; 615(1-2):66-74. PubMed ID: 17141279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The DNA topoisomerase IIbeta binding protein 1 (TopBP1) interacts with poly (ADP-ribose) polymerase (PARP-1).
    Wollmann Y; Schmidt U; Wieland GD; Zipfel PF; Saluz HP; Hänel F
    J Cell Biochem; 2007 Sep; 102(1):171-82. PubMed ID: 17340632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment.
    Sakamoto-Hojo ET; Balajee AS
    Anticancer Agents Med Chem; 2008 May; 8(4):402-16. PubMed ID: 18473725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
    Li R; Zhao W; Jin C; Xiong H
    Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
    Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage.
    Piao L; Nakagawa H; Ueda K; Chung S; Kashiwaya K; Eguchi H; Ohigashi H; Ishikawa O; Daigo Y; Matsuda K; Nakamura Y
    Genes Chromosomes Cancer; 2011 Jan; 50(1):13-24. PubMed ID: 20931645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.
    Alano CC; Kauppinen TM; Valls AV; Swanson RA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9685-90. PubMed ID: 16769901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trapping Poly(ADP-Ribose) Polymerase.
    Shen Y; Aoyagi-Scharber M; Wang B
    J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.